Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. It is grouped under the following drug class(es): Leishmaniasis agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Sitamaquina and sitamaquinum. Its PubChem CID is 42548.
Sitamaquine
| CAS No | 57695-04-2 |
|---|---|
| Molecular Formula | C21H33N3O |
| Molecular Weight | 343.50 g/mol |
| Synonyms | N',N'-diethyl-N-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
The listed CAS number is 57695-04-2.
The listed molecular formula is C21H33N3O.
The listed molecular weight is 343.50 g/mol.
N',N'-diethyl-N-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine.
The source lists Sitamaquina and sitamaquinum.